The number of shorts is now at the lowest level for 1 y. After...

The number of shorts is now at the lowest level for 1 y. After Sinclair left ATH, the number was almost 10 x higher, 1,122M, gradually decreasing during the past months of this year. This decline indicates that now the risk to short a stock is increasing, but after Sinclair left there was almost no risk in shorting. I am sure that among these shorters with these over 1 M shorted shares there are also some skillful shorting manipulators who have taken this opportunity Sinclair gave. The share price decline gives evidence that shorting after Sinclair left was very successful and perhaps also relatively easy when the market capital was small. It may well be that Sinclair's team has been a part of those who took this opportunity by giving the selling order to shorting manipulation experts to get rid of their ATH shares. I do not think Sinclair felt any pity for ATH after they had to leave ATH because of the severe claims ATH directors presented against them. Perhaps I myself had done it that way if I had been ousted.

Since Sinclair left ATH, the evidence of the value of PBT2 has grown by 6 scientific papers demonstrating the value of PBT2 in killing antibiotic-resistant bacteria killing over 1M every year. However, it will take time before PBT2 is in the pharmacy. To do it without any ATH money makes it even more difficult, perhaps. The next deadline is the 20th of Feb. I hope that the management will give some essential info before that.

On the ATH434 side, the start of the phase 2 study is also a big thing. There were only 2 preclinical studies published during this year, the "hyposmia" paper in a PD mouse model and an MSA murine model paper by Finkelstein et al. In spite of this number being quite small, it is evident that many other studies have been done but not published, perhaps at least about brain injury and AD (according to the annual report). I like the "hyposmia-paper" a lot. It was done by the old Prana team and is supporting the usage of ATH434 as preventive medication many years before the symptoms of PD would start. Now waiting for the results of the primate PD study supported by the Michael Fox foundation 2 years ago.